- Home
- AGEN vs ANVS Comparison
AGEN vs ANVS Comparison
Compare AGEN & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ANVS
- Stock Information
- Founded
- AGEN 1994
- ANVS 2008
- Country
- AGEN United States
- ANVS United States
- Employees
- AGEN N/A
- ANVS N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- ANVS Health Care
- Exchange
- AGEN Nasdaq
- ANVS Nasdaq
- Market Cap
- AGEN 96.2M
- ANVS 110.4M
- IPO Year
- AGEN 2000
- ANVS 2020
- Fundamental
- Price
- AGEN $2.86
- ANVS $6.78
- Analyst Decision
- AGEN Buy
- ANVS Strong Buy
- Analyst Count
- AGEN 3
- ANVS 6
- Target Price
- AGEN $9.33
- ANVS $29.67
- AVG Volume (30 Days)
- AGEN 576.6K
- ANVS 232.1K
- Earning Date
- AGEN 11-12-2024
- ANVS 11-08-2024
- Dividend Yield
- AGEN N/A
- ANVS N/A
- EPS Growth
- AGEN N/A
- ANVS N/A
- EPS
- AGEN N/A
- ANVS N/A
- Revenue
- AGEN $160,427,000.00
- ANVS N/A
- Revenue This Year
- AGEN N/A
- ANVS N/A
- Revenue Next Year
- AGEN $0.04
- ANVS N/A
- P/E Ratio
- AGEN N/A
- ANVS N/A
- Revenue Growth
- AGEN 59.00
- ANVS N/A
- 52 Week Low
- AGEN $2.50
- ANVS $4.53
- 52 Week High
- AGEN $19.69
- ANVS $22.49
- Technical
- Relative Strength Index (RSI)
- AGEN 28.17
- ANVS 33.11
- Support Level
- AGEN $2.50
- ANVS $6.68
- Resistance Level
- AGEN $2.89
- ANVS $8.93
- Average True Range (ATR)
- AGEN 0.29
- ANVS 0.51
- MACD
- AGEN -0.07
- ANVS -0.19
- Stochastic Oscillator
- AGEN 18.75
- ANVS 14.43
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.